Data gathered: November 14
Alternative Data for Sarepta Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 24 | Sign up | Sign up | Sign up |
| Sentiment | 63 | Sign up | Sign up | Sign up |
| Webpage traffic | 22,000 | Sign up | Sign up | Sign up |
| Employee Rating | 86 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| Patents | 121 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 776 | Sign up | Sign up | Sign up |
| Facebook Followers | 9,234 | Sign up | Sign up | Sign up |
| Instagram Followers | 5,240 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 20 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,842 | Sign up | Sign up | Sign up |
| Twitter Followers | 5,711 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $83,000 | Sign up | Sign up | Sign up |
| Business Outlook | 85 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,469 | Sign up | Sign up | Sign up |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Price | $109.11 |
| Target Price | Sign up |
| Volume | 1,430,000 |
| Market Cap | $10.9B |
| Year Range | $109.11 - $163.85 |
| Dividend Yield | 0% |
| PE Ratio | 74.23 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They SeemNovember 12 - Yahoo |
 |
QRG Capital Management Inc. Purchases Shares of 1,969 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)November 12 - ETF Daily News |
|
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Buy” by AnalystsNovember 12 - ETF Daily News |
|
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 7.6% on Analyst DowngradeNovember 8 - ETF Daily News |
 |
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next StepNovember 7 - SeekingAlpha |
|
Van ECK Associates Corp Has $8.85 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)November 7 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 467M | 129M | 338M | 34M | 40M | 0.340 |
| Q2 '24 | 363M | 139M | 224M | 6.5M | 19M | 0.070 |
| Q1 '24 | 413M | 128M | 286M | 36M | 46M | 0.370 |
| Q4 '23 | 397M | 135M | 262M | 46M | 46M | 0.470 |
| Q3 '23 | 332M | 149M | 183M | -41M | -28M | -0.460 |
Insider Transactions View All
| Estepan Ian Michael filed to sell 33,946 shares at $137.4. September 3 '24 |
| Chambers Michael Andrew filed to buy 284,034 shares at $134.7. August 20 '24 |
| Chambers Michael Andrew filed to buy 260,102 shares at $133.1. August 20 '24 |
| Chambers Michael Andrew filed to buy 278,386 shares at $134.1. August 20 '24 |
| Brown Ryan Edward filed to sell 45,267 shares at $160.3. June 25 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
Aug 21, 23 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Jul 11, 23 | Sell | $1K - $15K |
| Daniel S. Goldman Democrat |
May 19, 23 | Sell | $15K - $50K |
Read more about Sarepta Therapeutics (SRPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Sarepta Therapeutics?
The Market Cap of Sarepta Therapeutics is $10.9B.
What is Sarepta Therapeutics' PE Ratio?
As of today, Sarepta Therapeutics' PE (Price to Earnings) ratio is 74.23.
What is the current stock price of Sarepta Therapeutics?
Currently, the price of one share of Sarepta Therapeutics stock is $109.11.
How can I analyze the SRPT stock price chart for investment decisions?
The SRPT stock price chart above provides a comprehensive visual representation of Sarepta Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sarepta Therapeutics shares. Our platform offers an up-to-date SRPT stock price chart, along with technical data analysis and alternative data insights.
Does SRPT offer dividends to its shareholders?
As of our latest update, Sarepta Therapeutics (SRPT) does not offer dividends to its shareholders. Investors interested in Sarepta Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sarepta Therapeutics?
Some of the similar stocks of Sarepta Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.